维普中文期刊产品整合服务
24篇 您的检索式:作者名="Helton T"
    题名 作者 年代 出处 被引量
1Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT显示文摘Yttrium-90 (Y-90) radioembolization,also known as selective internal radiation therapy (SIRT),is a regional hepatic therapy used in the treatment of unresectable colorectal cancer (CRC) liver metastases. In SIRT,Y-90 impregnated microspheres are injected into the VASCULAR SUPPLY of hepatic tumor,leading to selective irradiation and necrosis of tumor TISSUE. While several studies demonstrate improved local control and survival with SIRT,the specific indications for this therapy have yet to be defined. Typically,SIRT is given in combination with chemotherapy as multimodal treatment for unresectable hepatic CRC. However,it HAS ALSO FOUND INCREASING USE as a salvage therapy in chemo-refractory patients. Herein,the authors describe their experience with SIRT as 'stand alone' therapy in a surgically-prohibitive,chemotherapy naive patient with hepatic CRC metastasis. The results suggest that Y-90 SIRT may have potential applications beyond its usual role as a palliative or salvage therapy for unresectable hepatic CRC.Sean Garrean Amanda Muhs James T Bui Michael J Blend Charles Owens William S Helton Nocif J Espat 2007World Journal of Gastroenterology2007,13,21:4
2What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?:a meta-analysis显示文摘 KUMBHANI D J HELTON T J 2005J Am Coll Cardiol2005,45,6:1
3Catalytic Hydroprocessong a Good Alternative to Solvent Processing 显示文摘T E Helton 1998Oil & Gas Journal1998,96,29:1
4Eicosapentaenoic acid (EPA) : an antiinflammatory omega-3 fat with potential clinical applications显示文摘Babcock T Helton WS Espat NJ 2000Nutrition2000,16,1112:1
5Lube oil processing-conclusion: Catalytic hydroprocessing a good alternative to solvent processing显示文摘Helton T E Degnan T F J Mazzone D N 1998Oil & Gas Journal1998,96,29:1
6Eicosapentaenoic acid (EPA) ; an anti - inflammatory omega -3 fat with po- tential clinical applications 显示文摘BABCOCK T HELTON WS ESPAT NJ 2000Nutrition2000,16,1112:1
7What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis显示文摘BAVRY A A KUMBHANI D J HELTON T J 2005J Am Coll Cardiol2005,45,6:1
8Eicosapentaenoic acid (EPA) : an antiinflammatory omega- 3 fat with potential clinical applications 显示文摘BABCOCK T HELTON W S ESPAT N J 2000Nutrition2000,16,1112:1
9Effect of L-carnitine treatment for valproate-induced hepatotoxicity显示文摘Bohan TP Helton E McDonald I Konig S Gazitt S Sugimoto T 2001Neurology2001,56,10:1
10Eicosapentaenoic acid (EPA): an antiinflammatory omega-3 fat with potential clinical applications显示文摘Babcock T Helton WS Espat NJ 2000Nutrition2000,16,1112:1
11Effect of L-carnitine treatment for valproate-induced hepatotoxicity显示文摘Bohan T P Helton E McDonald I 2001Neurology2001,56,10:1
12Survey of opinions on operative manage-ment of adhesive small bowel obstruction:laparoscopy versuslaparotomy in the state of Connecticut显示文摘Oyasiji T Helton SW 2011Surg Endosc2011,25,8:1
13Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials显示文摘BAVRY A A KUMBHANI D J HELTON T J 2006Am J Med2006,119,:1
14Eicosapentaenoic acid (EPA):an antiinflammatory N-3 fat with potential clinical applications显示文摘 Helton WS Espat NJ 2000Nutrition2000,16,:1
15Survey of opinions on operative management of adhesive small bowel obstruction:laparoscopy versus laparotomy in the state of Connecticut显示文摘Oyasiji T Helton SW 2011Surg Endosc2011,25,8:1
16Survey of opinions on operative manage- ment of adhesive small bowel obstruction: laparoscopy versus la- parotomy in the state of Connection显示文摘Oyasiji T Helton SW 2011Surg Endosc2011,25,8:1
17Rare long-term survivors of pancreatic adenocarcinoma without curative resection显示文摘Long-term outcome data in pancreatic adenocarcinoma are predominantly based on surgical series, as resection is currently considered essential for longterm survival. In contrast, five-year survival in nonresected patients has rarely been reported. In this report, we examined the incidence and natural history of ≥ 5-year survivors with non-resected pancreatic adenocarcinoma. All patients with pancreatic adenocarcinoma who received oncologic therapy alone without surgery at our institution between 1995 and 2009 were identified. Non-resected ≥ 5-year survivors represented 2%(11/544) of all non-resected patients undergoing treatment for pancreatic adenocarcinoma, and 11%(11/98) of ≥ 5-year survivors. Nine patients had localized tumor and 2 metastatic disease at initial diagnosis. Disease progression occurred in 6 patients, and the local tumor bed was the most common site of progression. Six patients suffered from significant morbidities including recurrent cholangitis, second malignancy, malnutrition and bowel perforation. A rare subset of patients with pancreatic cancer achieve longterm survival without resection. Despite prolonged survival, morbidities unrelated to the primary cancer were frequently encountered and a close follow-up is warranted in these patients. Factors such as tumor biology and host immunity may play a key role in disease progression and survival.Stephen Y Oh Alicia Edwards Margaret T Mandelson Bruce Lin Russell Dorer W Scott Helton Richard A Kozarek Vincent J Picozzi 2015World Journal of Gastroenterology2015,21,48:1
18What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? a meta-analysis显示文摘Bavry A Kumbhani D Helton T 2005J Am Coll Cardiol2005,45,:1
19Local zones of endoplasmic reticulum complexity confine cargo in neuronal dendrites显示文摘Cui-Wang T Hanus C Cui T Helton TA Watson D Harris KM 2012Cell2012,148,12:1
20Eicosapentaenoic acid (EPA): an an- tiinflammatory omega - 3 fat with potential clinical applications显示文摘Babcock T Helton WS Espat NJ 2000Nutrition2000,16,1112:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费